Alaunos Registers 382.1M Shares for Resale From Velaris Merger and $350M PIPE
TCRT has more than doubled off its 52-week low of $0.719.
Summary
Alaunos registered 382.1 million shares for resale by the Velaris merger and PIPE investors, against 4.2 million shares currently outstanding. Conversion is gated on a shareholder vote to approve the conversion and raise the authorized share count.
Key Events · Financing and Capital Events · TCRT
-
382.1M Shares Registered for Resale
The S-3 covers 382,090,789 shares: 105,286,000 from Series B conversion, 33,054,000 from merger Series C, 687,789 PIPE common shares and 243,063,000 from PIPE Series C conversion. Alaunos sells nothing and receives no proceeds.
-
Conversion Gated on Shareholder Vote
Preferred converts at 1,000 common per share only after stockholders approve the Conversion Approval and an increase in authorized Common Stock, currently 50,000,000 shares versus 4,208,359 outstanding as of November 11, 2026.
-
Paragon Deal Economics Disclosed
Assumed Paragon option carries $18.5M of pre-closing development costs, a $3.0M research initiation fee per program capped at $12.0M, up to $62.5M in milestones per product, high single-digit royalties and two 1.00% warrants.
-
Paragon License Reversion Trigger
Paragon may reclaim licensed rights if stockholders' equity does not exceed $200 million at the end of the second full fiscal quarter after the October 13, 2026 closing, or if freely tradeable shares are not delivered within 120 days of a warrant exercise.
Analysis · TCRT · Life Sciences
This S-3 puts hard numbers on the October 13 Velaris merger and concurrent $350 million PIPE for the first time: 382,090,789 shares are being registered for resale, against only 4,208,359 shares of Common Stock outstanding as of November 11. No proceeds flow to the company, which is not selling anything; the selling stockholders are. The real constraint is that the preferred stock cannot convert until shareholders approve both the conversion and an increase in authorized Common Stock from the current 50,000,000 shares, so the overhang is registered but not yet tradable. The filing also lays out the Paragon option economics assumed in the merger: $18.5 million of pre-closing development costs already owed, $3.0 million per research program (capped at $12.0 million), up to $62.5 million in milestones per product, high single-digit royalties, and two 1.00% warrants. Paragon can also take back the license if stockholders' equity does not exceed $200 million at the second full fiscal quarter after closing — a real condition given the company's thin equity base.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.72 to $4.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.